Wikipedia:Articles for deletion/Cowin Capital

The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was keep‎. ✗plicit 03:25, 19 June 2023 (UTC)[reply]

Cowin Capital[edit]

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

Not evidence of significant coverage outside of its own published material and a couple of secondary references. The firm's notability might be considered insufficient if it doesn't meet these guidelines. NortonAngo (talk) 15:15, 29 May 2023 (UTC)[reply]

Note: This discussion has been included in the deletion sorting lists for the following topics: Finance, Companies, and China. Spiderone^{(Talk to Spider)} 15:57, 29 May 2023 (UTC)[reply]
Keep: Please check WP:BEFORE before nominating again, none of these references are published by Cowin Capital. I'm not seeing any reliability issues with the references that are used, either. Dylan | ✉ | ✓ 17:01, 29 May 2023 (UTC)[reply]
Strong delete Only one source could qualify as a reliable source - the London Business School. The rest are not reliable at all. The page should be deleted as it does not fulfill the NCORP criteria. --159.118.233.94 (talk) 13:02, 30 May 2023 (UTC)[reply]

Keep per the significant coverage in multiple independent reliable sources.
1. "Case Study: Yin and Yang" (PDF). No. 7. Coller Institute of Private Equity. London Business School. Winter 2012. pp. 16–17. Archived from the original (PDF) on 2023-06-04. Retrieved 2023-06-04.
  The article notes: "Against this background, the Shenzhen Cowin Venture Capital fund represents a perfect opportunity for a case study by the London Business School’s Coller Institute of Private Equity. ... The result is Cowin Capital: The Evolution of the Chinese PE & VC Industry, produced by Professor Talmor, together with MBA students Wei Cao, Masaki Takeda and Carolyn Tiet. Founded during the dot-com bubble in 2000, Cowin survived the ensuing crash that saw many nascent Chinese VC funds fold. Not only that, but it went on to achieve impressive success following the regulatory changes of the mid- 2000s. "The key questions are: how Cowin has managed to transform itself and what it is doing to perpetuate its success," says Talmor. Cowin grew from cautious beginnings to become one of Shenzhen's leading PE lights. Having launched six funds in total, the firm currently manages RMB 5.5bn of capital and assets valued at more than RMB 7.5bn. As of June 2012, 31 of its investments had resulted in distributions to Cowin's investors, including 23 IPOs and eight buybacks or trade sales. Its success has earned Cowin founder Weihe Zheng the moniker "Star Shooter"."
2. Liu, Pingsheng 刘平生; He, Jie 何杰, eds. (2022). 深圳经济特区金融40年 [40 years of finance in Shenzhen Special Economic Zone] (in Chinese). Beijing: Social Sciences Literature Press. ISBN 978-7-52-019390-0. Retrieved 2023-06-04 – via Google Books.
  The book has an entire subsection about the company. The book notes: "2000年6月26日,同创伟业成。 2004年,随中小的开,同创伟业资的达基实现IPO,随后在2005年轴研科技也顺利实现了IPO,同创伟业在中小开前50 中占据两。达基是同创伟业首个IPO项目,也是本土创首个上例。 2007年6月26日,同创伟业先发起成中国一有合伙制"
  From Google Translate: "On June 26, 2000, Cowin Capital was established. In 2004, with the opening of small and medium-sized enterprises, Daji, which was funded by Cowin Capital, realized its IPO, and then in 2005, Axis Technology also successfully realized its IPO, and Cowin Capital occupied two of the top 50 small and medium-sized enterprises. Daji is the first IPO project of Cowin Capital, and it is also the first domestic case. On June 26, 2007, Cowin Capital was the first to initiate into China's one-owned partnership system."
3. He, Shasha 何莎莎 (2010). "同创伟业顺势而为" [Cowin Capital seizes opportunities]. 投资与合作 [Investment and Cooperation] (in Chinese). No. 9. ISSN 1004-387X. Retrieved 2023-06-04 – via CQVIP [zh].
  The abstract notes: "用硕果累累来形容深圳市同创伟业创业投资有限公司（以下简称为同创伟业）最近的投资表现一点都不为过。 2010年8月12日乐视网在深圳交易所创业板挂牌、8月3日深圳欧菲光科技正式在深交所上市、7月8日湛江国联水产开发股份有限公司登陆深交所创业板、5月26日康芝药业于深交所创业板实现上市"
  From Google Translate: "It is not an exaggeration to describe the recent investment performance of Shenzhen Cowin Capital, Ltd. (hereinafter referred to as Cowin Capital) with fruitful results. On August 12, 2010, LeTV was listed on the GEM of the Shenzhen Stock Exchange. On August 3, Shenzhen OFILM Technology was officially listed on the Shenzhen Stock Exchange. On July 8, Zhanjiang Guolian Aquatic Development Co., Ltd. landed on the Shenzhen Stock Exchange’s GEM. On May 26 Kangzhi Pharmaceutical was listed on the Growth Enterprise Market of Shenzhen Stock Exchange."
4. Zheng, Weihe 郑伟鹤 (2011). "同创伟业健康成长" [Cowin Capital: healthy growth]. 投資与合作 [Investment and Cooperation Magazine] (in Chinese). No. 2. ISSN 1004-387X. Retrieved 2023-06-04 – via CQVIP [zh].
  The abstract notes: "2010年，同创伟业共投资了30个项目，并且有8个项目IPO，平均回报率达到10倍。"
  From Google Translate: "In 2010, Cowin Capital invested in a total of 30 projects, and had 8 IPO projects, with an average rate of return of 10 times."
5. Zhao, Di 赵迪 (2009). "郑伟鹤:做创业者的同行者" [Zheng Weihe: being a fellow entrepreneur]. 股市动态分析 [Stock Market Dynamic Analysis] (in Chinese). No. 12. ISSN 1001-0432. Retrieved 2023-06-04 – via CQVIP [zh].
  The abstract notes: "2000年,郑伟鹤创建了深圳市同创伟业投资有限公司,从一名律师转型为一名私募股权投资基金经理人。截至2009年6月,在同创伟业投资的项目中,已经有四个项目在中小企业板上市。如今,已经跨入不惑之年的郑伟鹤依旧在执着于他的PE理想。正如他公司的名称———同创伟业所诠释的那样,做创业者的同行者。"
  From Google Translate: "In 2000, Zheng Weihe founded Shenzhen Cowin Capital, transforming from a lawyer to a private equity investment fund manager. As of June 2009, among the projects invested by Cowin Capital, four projects have been listed on the SME board. Today, Zheng Weihe, who has entered his forties, is still obsessed with his PE ideal. As the name of his company --- Cowin Capital explained, he is a fellow entrepreneur."
6. Yu, Yong 于勇 (2011). "同创伟业2010年参投上市项目半数变脸" [In 2010, Cowin Capital (simplified Chinese: 同创伟业; traditional Chinese: 同創偉業) to pass Wikipedia:Notability#General notability guideline, which requires "significant coverage in reliable sources that are independent participated in half of the listed projects and changed its face]. 股市动态分析 [Stock Market Dynamic Analysis] (in Chinese). No. 26. ISSN 1001-0432. Retrieved 2023-06-04 – via CQVIP [zh].
  The abstract notes: "如果说一家医药企业不以患者安全为最高准则,那么即使它倒下,也将是社会的一大收获。而一家资金显赫的创投企业,投资资金入股一家这样的医药企业,作为如今盛行的创业投资资金Pre-IPO项目,PE盛宴之后。"
  From Google Translate: "Abstract: If a pharmaceutical company does not regard patient safety as the highest criterion, even if it falls, it will be a great harvest for the society. And a well-funded venture capital company invests funds in such a pharmaceutical company, as a pre-IPO project of venture capital funds that is prevalent today, after the PE feast."
7. Deng, Shuanglin 邓双琳 (2020). "同创伟业捕捉科创板"隐形冠军"" [Cowin Capital captures the "hidden champion" of the Science and Technology Innovation Board]. 创业邦 [Entrepreneur] (in Chinese). No. 7. ISSN 1674-3601. Retrieved 2023-06-04 – via CQVIP [zh].
There is sufficient coverage in reliable sources to allow Cowin Capital (simplified Chinese: 同创伟业; traditional Chinese: 同創偉業) to pass Wikipedia:Notability#General notability guideline, which requires "significant coverage in reliable sources that are independent of the subject".
Cunard (talk) 08:03, 4 June 2023 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, North America¹⁰⁰⁰ 03:10, 6 June 2023 (UTC)[reply]

Keep per Cunard. The person who loves reading (talk) 15:11, 11 June 2023 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, Liz ^{Read! Talk!} 03:22, 12 June 2023 (UTC)[reply]

Keep The first two references listed by Cunard above meets GNG/NCORP criteria for establishing notability. HighKing⁺⁺ 19:52, 17 June 2023 (UTC)[reply]

The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.